HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and raises the price target from $63 to $70.
- Headlines
- HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Raises Price Target to $70
HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Raises Price Target to $70
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
17:00
The contribution of AI to Russia's GDP may reach 11.2 trillion rubles before 2030, according to the Russian Savings Bank.
SBRCY0.00%
16:50
Electric Connector Technology: Autos connector products have entered the supply chains of major domestic automakers such as Great Wall, BYD, and Ideal.
16:49
According to Antaike, the total domestic refined tin production in November was 17,658 tons, a month-on-month increase of 5.6%.